Pfizer, BioNTech win lawsuit against CureVac over COVID vaccine patents in U.K.
by
Contributor since / Followers
Contributor since / Followers
2 months ago
greenleaf123/iStock via Getty Images
- Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) on Tuesday successfully convinced London’s High Court to invalidate two patents held by rival CureVac (NASDAQ:CVAC) related to the messenger RNA (mRNA) technology upon which the duo’s blockbuster COVID-19 vaccine is based.
- The litigation is part of the U.K. segment of a broader legal battle between Pfizer (PFE), BioNTech (BNTX), and CureVac (CVAC), spanning countries from the U.S. to Germany.
- Pfizer (PFE) and BioNTech (BNTX), whose messenger-RNA-based COVID-19 vaccine Comirnaty was the first to win the U.S. regulatory nod in 2020, initially filed the lawsuit against the German vaccine developer in September 2022.
- Several lawsuits filed by CureVac (CVAC) against its German rival BioNTech (BNTX) in its home country had preceded the companies’ U.K. lawsuit.